Thrombosis And Hemostasis Biomarkers Market Report 2026

Thrombosis And Hemostasis Biomarkers Market Overview

• Thrombosis And Hemostasis Biomarkers market size has reached to $5.17 billion in 2025 • Expected to grow to $7.37 billion in 2030 at a compound annual growth rate (CAGR) of 7.3% • Growth Driver: Surge In Demand For Precise And Targeted Therapies Driving Growth Of The Market Due To Advancements In Genetic And Molecular Understanding • Market Trend: Innovative Automated Solutions Strengthening Diagnostic Efficiency • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Thrombosis And Hemostasis Biomarkers Market?

Thrombosis and hemostasis biomarkers refer to biological molecules that provide insight into the processes of blood clot formation and the regulation of bleeding. These biomarkers help monitor the delicate balance between clot formation and dissolution, playing a crucial role in understanding vascular health and coagulation disorders. The main products of thrombosis and hemostasis biomarkers include reagents and consumables and analyzers. Reagents and consumables refer to the essential chemical substances and disposable laboratory materials, such as assay kits, buffers, calibrators, and control solutions, used to detect, quantify, and analyze biomarkers involved in blood clotting and bleeding disorders. It uses various types of tests, such as D-dimer, anti-thrombin iii, plasminogen, soluble fibrin, factor VIII, prothrombin (PT), activated partial thromboplastin time (APTT) test, and others, and is applied in cardiovascular disorders, neurological disorders, oncology, pregnancy-related disorders, and orthopedic procedures. It is used by several end users, including hospitals, diagnostic laboratories, pharmaceutical companies, academic institutions, and home healthcare settings.

What Is The Thrombosis And Hemostasis Biomarkers Market Growth Forecast?

The thrombosis and hemostasis biomarkers market size is expected to see strong growth in the next few years. It will grow to $7.37 billion in 2030 at a compound annual growth rate (CAGR) of 7.3%. The growth in the forecast period can be attributed to technological advancements in fully automated analyzers, increasing adoption of poct coagulation devices, rising investment in personalized medicine, expansion of pharmaceutical and diagnostic research, development of novel biomarkers for early disease detection. Major trends in the forecast period include growing adoption of advanced coagulation analyzers, rising demand for point-of-care testing solutions, increased focus on early detection of cardiovascular disorders, expansion of diagnostic reagents and immunoassay kits, integration of biomarker testing in personalized medicine.

Global Thrombosis And Hemostasis Biomarkers Market Segmentation

1) By Product: Reagents And Consumables, Analyzers 2) By Test Type: D-Dimer, Anti-Thrombin III, Plasminogen, Soluble Fibrin, Factor VIII, Post-Thrombin (PT), Activated Partial Thromboplastin Time (APTT) Test, Other Test Types 3) By Application: Cardiovascular Disorders, Neurological Disorders, Oncology, Pregnancy-Related Disorders, Orthopedic Procedures 4) By End User: Hospitals, Diagnostics Laboratories, Pharmaceutical Companies, Academic Institutions, Home Healthcare Settings Subsegments: 1) By Reagents And Consumables: Coagulation Reagents, Control And Calibration Materials, Immunoassay Kits 2) By Analyzers: Fully Automated Coagulation Analyzers, Semi-Automated Coagulation Analyzers, Point-Of-Care Coagulation Devices

What Is The Driver Of The Thrombosis And Hemostasis Biomarkers Market?

The growing demand for precise and targeted therapies is expected to drive the growth of the thrombosis and hemostasis biomarkers market going forward. Precise and targeted therapies refer to advanced treatment approaches that specifically address the molecular and genetic characteristics of a patient’s disease, aiming to enhance efficacy while minimizing adverse effects. Demand for precise and targeted therapies is rising due to the growing understanding of genetic and molecular variations in diseases, which allows for treatments that are more tailored to individual patients, enhancing effectiveness and reducing side effects. Demand for precise and targeted therapies supports thrombosis and hemostasis biomarkers by enabling the development of more accurate diagnostic tools that identify specific biomarkers, leading to better-targeted treatments for clotting disorders and improved patient outcomes. For instance, in March 2024, according to Novotech, an Australia-based contract research organization (CRO), of the 217 FDA-approved oncology therapies by the end of 2023, 43% are classified as precision oncology treatments, with 78 incorporating deoxyribonucleic acid (DNA) or next-generation sequencing (NGS)-detectable biomarkers. Therefore, the growing demand for precise and targeted therapies will propel the growth of the thrombosis and hemostasis biomarkers industry.

Key Players In The Global Thrombosis And Hemostasis Biomarkers Market

Major companies operating in the thrombosis and hemostasis biomarkers market are F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Abbott Laboratories, Siemens Healthineers AG, Becton Dickinson and Company (BD), Mayo Clinic Laboratories, bioMérieux S.A., Beckman Coulter Inc., QuidelOrtho Corporation, Bio-Rad Laboratories Inc., ARUP Laboratories, HORIBA Ltd., Werfen S.A., Pathkind Diagnostics Pvt. Ltd., Diagnostica Stago, Agilus Diagnostics, Helena Laboratories Corporations, Cleveland Clinic Laboratories, Diazyme Laboratories Inc., Biomedica Diagnostics Inc., Atlas Medical GmbH

Global Thrombosis And Hemostasis Biomarkers Market Trends and Insights

Major companies operating in the thrombosis and hemostasis biomarkers market are focusing on developing advanced solutions such as automation integration, which allows for streamlined laboratory workflows and increased testing precision. Automation integration in a clinical laboratory refers to the use of interconnected automated systems, instruments, and robotics designed to perform laboratory testing processes with minimal human intervention. For instance, in April 2024, Siemens Healthcare, a Germany-based medical technology company, and Sysmex Corporation, a Japan-based medical technology company, launched the combined portfolio of hemostasis testing solutions to laboratories, which is a wide range of proven instruments and assay kits designed to support laboratory testing for various bleeding and clotting disorders and enables dynamic sample routing with automated reflex testing, speeding up turnaround times and increasing throughput without the need for additional staff. Additionally, automation facilitates centralized control and real-time monitoring, allowing for intelligent workflow management, quality control integration, and resource optimization.

What Are Latest Mergers And Acquisitions In The Thrombosis And Hemostasis Biomarkers Market?

In February 2024, Procuritas Capital Investors, a Sweden-based private equity fund, acquired Precision BioLogic (PBI) and Affinity Biologicals for an undisclosed amount. This deal aims to strengthen Procuritas' position in the fast-growing thrombosis and hemostasis diagnostics market by leveraging Precision BioLogic’s FDA-cleared reagents, plasma-based products, and strong R&D capabilities, alongside Affinity Biologicals’ custom assay services to capitalize on global healthcare trends. Precision BioLogic (PBI) is a Canada-based provider of diagnostic products for blood coagulation disorders, and Affinity Biologicals is a Canada-based company manufacturing products used in thrombosis and hemostasis research and diagnostics.

Regional Insights

North America was the largest region in the thrombosis and hemostasis biomarkers market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Thrombosis And Hemostasis Biomarkers Market?

The thrombosis and hemostasis biomarkers market consists of revenues earned by entities by providing services such as clinical laboratory testing services, patient risk assessment services, disease monitoring services, and research and development services. The market value includes the value of related goods sold by the service provider or included within the service offering. The thrombosis and hemostasis biomarkers market also includes sales of clot waveform analysis kits, microfluidic coagulation testing devices, and factor assay kits. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Thrombosis And Hemostasis Biomarkers Market Report 2026?

The thrombosis and hemostasis biomarkers market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the thrombosis and hemostasis biomarkers industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.